Efavirenz 400 vs 600 mg combined with lamivudine and tenofovir in treatment-naïve HIV-infected patients in China: A randomized, multi-centered, controlled trial

International Journal of Infectious Diseases 2026 Open access

Read full text
Authors: Qi Hang, Wang Ziyan, Song Xiaojing, Wang Min, Ding Haibo, Ye Hanhui, Zhihao Meng, He Shenghua, He Yun, Li Linghua, Shen Yinzhong, Xiong Yong
+2 more Ma Ping, Li Taisheng
DOI: 10.1016/j.ijid.2026.108859
Cited by: 1
References: 11

Abstract

BACKGROUND: Optimizing efavirenz (EFV) dosing to minimize adverse events (AEs) remains a critical issue. Studies indicate that reducing the EFV dose from 600 to 400 mg daily lowers side effect intensity while maintaining virological suppression. We previously showed that 600 mg daily EFV may lead to unnecessarily high exposure in Chinese patients, but the long-term efficacy and safety of dose reduction beyond 48 weeks in this population remain unknown. METHODS: We conducted a multicenter, randomized controlled trial comparing EFV 400 vs 600 mg, each combined with lamivudine (3TC) and tenofovir (TDF), in antiretroviral therapy-naïve Chinese adults with human immunodeficiency virus (HIV)-1. The primary endpoint was virological suppression (HIV-ribonucleic acid [RNA]

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

Publication details

Journal / source
International Journal of Infectious Diseases
Publisher
Elsevier BV
Volume
170
Pages
108859–108859
Publication date
2 June 2026
Language
EN